Small Molecule DPP4 Inhibitors for Alveolar Type 2 Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS) are inadequate in promoting the reparative proliferation of alveolar epithelial type 2 (AEC2) cells, leading to insufficient repair of the alveolar epithelial barrier and progression of disease.
Innovation Solution
Development of a compound that selectively promotes the proliferation of AEC2 cells, inhibits dipeptidyl peptidase IV (DPP4), and is used in pharmaceutical compositions to treat pulmonary diseases, thereby enhancing alveolar repair and reducing disease severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for IPF and ARDS are used, then disease progression is managed, but AEC2 cell proliferation is insufficient and alveolar repair is inadequate
Solution Approach 1:
The patent employs parameter changes by modifying chemical structures (formulas I, II, and III with various substituents R1-R11) to optimize the compound's ability to stimulate AEC2 proliferation. By systematically varying molecular parameters such as alkyl chain lengths, hydroxyl group positions, and ring structures, the invention achieves enhanced proliferative effects compared to existing treatments
Solution Approach 2:
The patent introduces a small molecule compound as an intermediary substance that mediates between the treatment administration and the AEC2 cells. This compound acts as a signaling mediator that specifically targets AEC2 proliferation pathways, thereby improving repair efficacy without directly applying complex therapeutic interventions
2Reliability
If AEC2 proliferation is stimulated to enhance alveolar repair, then disease severity is reduced, but selectivity for AEC2 versus other cell types must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that selectively interact with AEC2 cells. The chemical structures contain particular functional groups and spatial arrangements (e.g., specific hydroxyl patterns, ring configurations) that create localized recognition elements, enabling the compound to target AEC2s specifically while sparing other cell types in the lung
Solution Approach 2:
Instead of attempting to inhibit unwanted cell proliferation, the patent inverts the approach by specifically stimulating AEC2 proliferation through unique molecular recognition. The compound works by being selectively taken up or bound by AEC2s due to their specific surface characteristics, thereby achieving cell-type-specific effects through the reverse logic of positive selection rather than negative inhibition
3Reliability
If exogenous factors (IL-6 or hyaluronic acid) are used to restore AEC2 proliferation, then disease severity is inhibited in mouse models, but treatment complexity and potential off-target effects increase
Solution Approach 1:
The patent extracts the essential proliferative signaling function from complex exogenous factors like IL-6 and hyaluronic acid. By identifying and replicating only the critical proliferative stimulus in a simplified small molecule format, the invention achieves the same therapeutic effect (restoring AEC2 proliferation) without the complexity, cost, and potential side effects of using large protein-based cytokines or polysaccharide molecules
Solution Approach 2:
The patent employs stable, orally bioavailable small molecule compounds that can be administered in simple regimens compared to complex biologic therapies. These small molecules serve as disposable, self-contained therapeutic agents that do not require complex delivery systems, storage conditions, or administration protocols, thereby simplifying the treatment regimen while maintaining efficacy
Data Source
AI summary
The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). The compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology, for example, derives from epithelial degeneration and maladaptive remodeling, such as pulmonary diseases like idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and infant respiratory distress syndromes (IRDS).